Gene Therapy for Diabetic Macular Edema
Primary Purpose
Diabetic Macular Edema
Status
Recruiting
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
FT-003
Sponsored by
About this trial
This is an interventional treatment trial for Diabetic Macular Edema
Eligibility Criteria
Inclusion Criteria: Subjects that are willing and able to follow study procedures; Female or male patients ≥18 years old at the time of signing the ICF; Clinically diagnosed with CI-DME HbA1c≤10% The best corrected visual acuity (BCVA) of the studied eye is ≤ 73 letters Exclusion Criteria: Presence of any other intraocular diseases other than CI-DME in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator
Sites / Locations
- Tianjin Medical University Eye HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm Type
Experimental
Experimental
Experimental
Arm Label
FT003 Dose 1
FT003 Dose 2
FT003 Dose 3
Arm Description
Low dose of FT-003
Mid dose of FT-003
High dose of FT-003
Outcomes
Primary Outcome Measures
Safety and tolerability after FT-003 injection
Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)
Secondary Outcome Measures
Preliminary effectiveness after FT-003 injection
Changes in best-corrected visual acuity (BCVA) of the studied eye from baseline
Full Information
NCT ID
NCT05916391
First Posted
June 14, 2023
Last Updated
June 14, 2023
Sponsor
Frontera Therapeutics
Collaborators
Tianjin Medical University Eye Hospital, Peking Union Medical College Hospital, The First Affiliated Hospital of Zhengzhou University
1. Study Identification
Unique Protocol Identification Number
NCT05916391
Brief Title
Gene Therapy for Diabetic Macular Edema
Official Title
An Open-label, Multy-center, Dose-escalation Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of FT-003 in Subjects With Diabetic Macular Edema
Study Type
Interventional
2. Study Status
Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 19, 2023 (Actual)
Primary Completion Date
May 1, 2025 (Anticipated)
Study Completion Date
May 1, 2028 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Frontera Therapeutics
Collaborators
Tianjin Medical University Eye Hospital, Peking Union Medical College Hospital, The First Affiliated Hospital of Zhengzhou University
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
FT-003 is a gene therapy product developed for the treatment of central involvement diabetic macular edema (CI-DME). Diabetic retinopathy is one of the most common microvascular complications of diabetes mellitus, and diabetic macular edema is the main cause of vision loss in patients with diabetic retinopathy. In the latest guidelines, anti-VEGF therapy is preferred for CI-DME. Administration of FT-003 has the potential to treat CI-DME by providing intraocular protein which is durable expressed in therapeutic level. FT-003 is designed to reduce the current treatment burden which often results in undertreatment and vision loss in patients with CI-DME receiving anti-VEGF therapy in clinical practice.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetic Macular Edema
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Model Description
Central Involvement Diabetic Macular Edema
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
18 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
FT003 Dose 1
Arm Type
Experimental
Arm Description
Low dose of FT-003
Arm Title
FT003 Dose 2
Arm Type
Experimental
Arm Description
Mid dose of FT-003
Arm Title
FT003 Dose 3
Arm Type
Experimental
Arm Description
High dose of FT-003
Intervention Type
Genetic
Intervention Name(s)
FT-003
Intervention Description
Administration via intraocular injection
Primary Outcome Measure Information:
Title
Safety and tolerability after FT-003 injection
Description
Incidence and severity of AE (Common Terminology Criteria for Adverse Events 5.0)
Time Frame
Whthin 52 weeks after administration
Secondary Outcome Measure Information:
Title
Preliminary effectiveness after FT-003 injection
Description
Changes in best-corrected visual acuity (BCVA) of the studied eye from baseline
Time Frame
Whthin 52 weeks after administration
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Subjects that are willing and able to follow study procedures;
Female or male patients ≥18 years old at the time of signing the ICF;
Clinically diagnosed with CI-DME
HbA1c≤10%
The best corrected visual acuity (BCVA) of the studied eye is ≤ 73 letters
Exclusion Criteria:
Presence of any other intraocular diseases other than CI-DME in the studied eye that would affect the improvement of visual acuity and require treatment during the study for prevention or treatment of visual loss, as judged by the investigator
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Xinyan Li
Phone
+862158206061
Email
Xinyan.li@fronteratherapeutics.com
First Name & Middle Initial & Last Name or Official Title & Degree
Minghui Xue
Phone
+862158206061
Email
minghui.xue@fronteratherapeutics.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Xiaorong Li, Professor
Organizational Affiliation
Tianjin Medical University Eye Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Hanyi Min, Professor
Organizational Affiliation
Peking Union Medical College Hospital
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Guangming Wan, Professor
Organizational Affiliation
The First Affiliated Hospital of Zhengzhou University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Tianjin Medical University Eye Hospital
City
Tianjin
State/Province
Tianjin,China
ZIP/Postal Code
300392
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Xiaorong Li, Professor
12. IPD Sharing Statement
Plan to Share IPD
No
Learn more about this trial
Gene Therapy for Diabetic Macular Edema
We'll reach out to this number within 24 hrs